Real-world data back trastuzumab benefit

Even patients with HER2-positive breast cancer not completing treatment do well

New evidence of low recurrence rates among women with non-metastatic early breast cancer treated with trastuzumab is reassuring, say Australian researchers who have conducted the largest population-based study of outcomes among human epidermal growth factor 2-positive (HER2-positive) patients .